Rheumatology



23-25 April | Birmingham, UK

PROGRAMME

www.rheumatology.org.uk/conference



Twitter @RheumatologyUK #Rheum2013





Programme sponsored by



Welcome to Rheumatology 2013



I am very pleased to have this opportunity to welcome colleagues and friends, new and old to **Rheumatology 2013**.

We're all facing some real challenges with the changes going on in the NHS. This conference offers fantastic opportunities to learn about the latest in commissioning, to network with colleagues and share experiences. There's been no more important time to come together as a rheumatology community to learn, support each other, share knowledge and raise the profile of the vital work we all do.

It'd be impossible to list the many excellent sessions on offer this year, but needless to say that the programme has been designed to ensure there are sessions for everyone no matter what your profession or area of interest. I truly believe the conference gets better year on year and would like to thank everyone involved in supporting the event including our Heberden Committee, the BSR events team, speakers, chairs, abstract reviewers, prize judges, exhibitors and sponsors.

I hope that you find your time in Birmingham to be enjoyable, valuable and inspiring.

Dr Chris Deighton, BSR President



On behalf of the British Health Professionals in Rheumatology Council, I am delighted to welcome you to Birmingham and **Rheumatology 2013.**

With ten BHPR sessions, the Droitwich lecture, combined sessions with BSR as well as the rest of the programme this is the premier conference for AHPs working in rheumatology and MSK in primary or secondary care, whatever your role.

I am sure you will have an informative and educational conference but also I wish you an enjoyable conference, taking the opportunity to meet and socialise with friends and colleagues.

Mr Robert Field, BHPR President



A very warm welcome to everyone to **Rheumatology 2013**. We are again fortunate to have an unparalleled line-up of world experts, and this year we also have guests from the NHS Commissioning Board to give the latest information about the changes to the English healthcare system. The programme has fascinating lectures, seminars, symposia and workshops, and I recommend you take time to visit the research posters – there are more than ever before – as well as the exhibition, which showcases some of the latest industry developments.

Rheumatology 2013 is one of the ways we work to support our members; it offers interactive learning and professional development, as well as the opportunity to enjoy the company of your peers. At the end of your time here, I hope you'll return to your practice having gained new friends and brimming with exciting ideas.

I hope to meet as many members as I can during the conference – all the Society officers as well as your Council members are here to help you get the most out of the event. Please do give us feedback: we'll send out a survey, and you can tweet your highlights to @RheumatologyUK. We'll use your input in planning **Rheumatology 2014** in Liverpool next spring!

Mrs Laura Guest, BSR Chief Executive

Meet the team

The BSR events team has worked hard to make sure that **Rheumatology 2013** is as successful a conference as possible. If you have any problems at all while at the conference, please do come and speak to one of the team at the registration desk.



James Glavin Director of Events and Marketing



Lara Fasanya Senior Events Officer



Hannah Gardner Senior Events Officer



Saheeda Rahman Senior Events Officer



Lindsay McClenaghan Education & Events Officer



Twitter @RheumatologyUK #Rheum2013



LinkedIn Groups BSR Rheumatology 2013



Facebook The British Society for Rheumatology



The British Society for Rheumatology would like to acknowledge and thank our sponsors for their generous support, whose contribution to Rheumatology 2013 is invaluable.



Platinum sponsor

AbbVie | Stand 96

- Symposium Wednesday 24 April | 17.30- 19.15
- Innovation Theatre Talking AS, online ankylosing spondylitis assessment for your patients | Tuesday 23 April, 13.00- 13.30 and Thursday 25 April, 13.00- 13.30



Gold sponsor

Bristol-Myers Squibb Pharmaceuticals | Stand 76

- · Rheumatology 2013 programme sponsor
- Symposium Getting it right first time Biologics in RA: A debate Thursday 25 April, 07.30- 09.00

medac

Bronze sponsor

Medac GmbH | Stand 130

 Innovation Theatre – Early aggressive use of subcutaneous methotrexate: Financial and health benefits Wednesday 24 April, 11.00- 11.30



Bronze sponsor

Celgene Ltd | Stand 84

 Innovation Theatre – Looking inside the cell for a new perspective on Psoriatic Arthritis | Thursday 25 April, 10.30- 11.00



Platinum sponsor

Roche and Chugai | Stand 94

- Symposium Is disease remission achievable for Rheumatoid Arthritis Patients on Therapy without Methotrexate? Tuesday 23 April, 17.30- 19.15
- Innovation Theatre ANCA-associated vasculitis for Rheumatologists | Tuesday 23 April, 11.00- 11.30
- Combination therapy in RA: Methotrexate debate Wednesday 24 April, 10.30- 11.00



Silver sponsor

Pfizer Ltd | Stand 100

• Symposium - Wednesday 24 April, 07.30- 09.00



Bronze sponsor

Savient Pharma Ireland | Stand 46

 Innovation Theatre – Management of chronic Tophaceous Gout Tuesday 23 April 13.30- 14.00



Cyber Café sponsor Menarini Pharma UK | Stand 88

Conference at a glance | Tuesday 23 April 2013

Opening hours Registration: 07.30-19.30 Exhibition: 08.30-17.30

35

38

Morning

09.00 - 10.30

New insights on the pathogenesis and treatment of crystal arthritis Hall 1	25
Faster, safer, cheaper? Advances in orthopaedic science Hall 10	25
An embarrassment of riches: clinical research in rheumatoid arthritis Hall 4	26
BHPR: The experience of living with musculoskeletal problems and other conditions Hall 5	26
Oral abstracts: Connective tissue disease Hall 9	27
SIG: Spondyloarthropathy Hall 8b	27
BHPR SIG: Connective tissue disease Hall 8a	28
10.30 - 11.30	
Poster viewing and exhibition Tea and coffee	28
11.30 - 13.00	
BSR/BHPR: Facilitating adherence to treatment in rheumatology Hall 5	29
Osteoporosis: an update Hall 4	29
	30
Biologics in connective tissue disease Hall 1	00
 Biologics in connective tissue disease Hall 1 BHPR: Interactive panel discussion and problem solving to optimise work participation Hall 10 	30
BHPR: Interactive panel discussion and problem	
BHPR: Interactive panel discussion and problem solving to optimise work participation Hall 10	30

Afternoon

13.00 - 14.00	
Exhibition Lunch	
Registers open meeting Hall 5	33
BSR/BHPR: Post graduate research student network Hall 9	34

14.00 - 16.00

Jewels in the Crown | Hall 1

A conference highlight, the Jewels in the Crown session will showcase the top scoring abstracts, the Michael Mason and Garrod Prize winners and feature a keynote presentation from Bob Ricketts from the Department of Health/NHS **Commissioning Board**

16.00 - 16.30

Exhibition | Tea and Coffee

16.30 - 17.30	
Heberden Round Hall 1	35
17.30 – 19.15	
Industry supported symposium (including catering): Roche/Chugai Hall 5	36
19.30 – 21.30	

Presidents' reception | Birmingham Town Hall

KEY SESSION | BHPR **BSR/BHPR JOINT SESSION PRIMARY CARE ESSENTIALS IN RHEUMATOLOGY SCIENCE STREAM | TRAINEE STREAM KEYNOTE SESSION | ORAL ABSTRACTS** SPECIAL INTEREST GROUPS **INDUSTRY SUPPORTED SYMPOSIUM NETWORKING**

Conference at a glance | Wednesday 24 April 2013

Opening hours Registration: 07.00-18.30 Exhibition: 08.30-17.45

Morning			Afternoon
		_	
07.00 – 09.00			13.00 – 14
Industry supported symposium (inclu Actelion Hall 8	ding catering):	39	Exhibition
Industry supported symposium (inclu Pfizer Hall 5	ding catering):	41	14.30 - 1
09.00 - 10.30			Essenti Hall 1
Essentials in rheumatology: Disease Hall 1	management	41	BSR/BH impact,
Getting to grips with the use of soci rheumatology Hall 9	al media tools in	42	Hall 11
Ultrasound: what is in it for you? H	Hall 4	42	BHPR:
BHPR: Are our interventions cost-ef	fective? Hall 10	43	(ASpA)
Managing the care gap: implementing practice in primary care Hall 11a	ng evidence-based	43	Oral ab
Oral abstracts: Adolescent and your	ng adult Hall 7	44	
SIG: Education Executive Room 1		44	
BHPR: Measuring disease activity in	psoriatic	45	SIG: SL
arthritis Hall 11b			patient

10.30 - 11.30

Rheumatology's open access options and compliance 45 with funding bodies | Executive Room 1

10.30 - 11.30

Poster	viewing	and	exhibition	L	Tea	and	coffee	
1 03101	NEWING	anu	CAMUTION	L	ICa	anu	COLLEC	

11.30 - 13.00

Essentials in rheumatology: Symptoms diagnosis and management Hall 1	46
Arthritis pain: mechanisms, meaning and medicines Hall 4	47
The emerging role of epigenetics in rheumatic diseases Hall 5	47
BHPR plenary orals Hall 10	48
Oral abstracts: Primary care Hall 7	48
SIG: MSK disorders in ethnic minorities Hall 8a	49
SIG: Adolescent and young adult Hall 11a	49
SIG: Ultrasound Hall 11b	50

13.00 - 14	4.30
Exhibition	Lunch

GM | Hall 9

51

L6.00

Essentials in rheumatology: Clinical decision making Hall 1	51
BSR/BHPR: Longstanding musculoskeletal pain: impact, perceptual representations and treatment Hall 11a	51
Adolescent and young adult rheumatology Hall 10	52
BHPR: Clinical update on axial spondyloarthropathy (ASpA) Hall 4	52
Oral abstracts: OA and metabolic bone disease Hall 8b	53
ARMA: Musculoskeletal clinical networks in the new NHS landscape Hall 7	53
SIG: SLE Hall 8a	54
BHPR: Measuring disease activity in RA, when your patient is in remission Hall 11b	55

16.00 - 16.30

Exhibition | Tea and Coffee

16.30 - 17.30

46

Heberden Oration | Hall 1 55

17.30 - 19.15

Industry supported symposium (including catering): 56 AbbVie | Hall 5

19.30 – Late

Conference dinner | Shimla Pinks

56

Conference at a glance | Thursday 25 April 2013

Opening hours Registration: 07.00-18.30 Exhibition: 08.45-15.00

Morning

07.00 - 09.00

Industry supported symposium (including catering): Bristol-Myers Squibb | Hall 5

09.00 - 10.30

Ageing and the musculoskeletal system Hall 8b	59
Ask the experts Hall 9	60
Mortality in rheumatic disease Hall 4	60
BSR/BHPR: Advanced practice in osteoarthritis Hall 1	61
Oral abstracts: RA clinical Hall 7	61
SIG: Heritable disorders of connective tissue Hall 10	62
SIG: Sjögren's Hall 11	62
BHPR: Introducing cognitive behavioural approaches to rheumatic disease: top tips and tools for clinic Hall 8a	63

10.30 - 11.30

Poster viewing and exhibition | Tea and coffee

11.30 - 13.00

Oral abstracts: Science Hall 5	64
Interactive clinical teaching: osteoporosis Hall 9	64
Polymyalgia rheumatica and giant cell arteritis Hall 1	65
Droitwich Lecture and prizes Hall 11	65
Oral abstracts: Genetics Hall 8a	66
SIG: Scleroderma Hall 8b	66
SIG: Soft tissue rheumatism and sports medicine Hall 10	67

Afternoon

59

63

13.00 - 14.00	
Exhibition Lunch	
BHPR AGM Hall 11	68
BRITS AGM Hall 9	68
Standards, audits and guidelines working group open meeting Hall 7	68

14.00 - 15.30

Advances in cartilage biology: towards a better understanding of osteoarthritis Hall 4	69
Career development for new consultants Hall 9	69
Commissioning for rheumatology in a cold climate Hall 5	e 70
BHPR: The importance of health literacy in musculoskeletal disease Hall 8a	70
Oral abstracts: Spondyloarthritis Hall 7	71
SIG: Myositis Executive Room 2	71
SIG: Rheumatoid arthritis Hall 8b	72
BHPR: The use of ultrasound for nurses and allied health professionals Hall 10	d 72

16.00 - 17.30

SIG: Genetics Executive room 1	73
SIG: Osteoarthritis Hall 9	73
SIG: RA outcomes Hall 8a	74
SIG: Vasculitis Hall 8b	74
SIG: Interstitial lung disease Hall 7	75

17.30 Meeting close

KEY

SESSION | BHPR BSR/BHPR JOINT SESSION PRIMARY CARE ESSENTIALS IN RHEUMATOLOGY SCIENCE STREAM | TRAINEE STREAM KEYNOTE SESSION | ORAL ABSTRACTS SPECIAL INTEREST GROUPS INDUSTRY SUPPORTED SYMPOSIUM NETWORKING

Additional meetings

Tuesday 23 April 2013

Closed meeting (invitees only)

07.30 – 09.00 Standards, audits and guidelines working group committee meeting		Executive Room 1
10.15 - 11.15	10.15 – 11.15 OTTER trial steering committee meeting	
10.30 - 11.30	10.30 – 11.30 Simple Tasks	
12.00 – 13.00 BSR Higher Awards committee meeting		Executive Room 2
12.00 – 14.00 Orbit – investigator meeting		Executive Room 7
13.00 – 15.00 SWITCH investigator meeting		Executive Room 1
13.00 - 15.30	Foot and ankle expert meeting	Executive Room 2

Open meetings

13.00 - 14.00	Meeting in a box – NASS GP Back Pain Initiative	Hall 10
---------------	---	---------

Wednesday 24 April 2013

Closed meeting (invitees only)

07.00 – 09.00	07.00 – 09.00 BHPR Council committee meeting	
07.30 – 08.30	07.30 – 08.30 CMF Breakfast Meeting	
14.30 - 16.00	BSR US SIG business meeting	Executive Room 1
17.30 – 19.30	BSR AS anti-TNF guidelines meeting	Executive Room 2

Thursday 25 April 2013

Closed meeting (invitees only)

07.30 – 09.30	ERAN AGM	Executive Room 1
07.30 – 09.00	BSR GCA working group	Executive Room 2
10.30 - 12.30	Tractiss investigator meeting	Executive Room 1

General information 23-25 April 2013 | The ICC, Birmingham

IC







formulations^a

* RA: Rheumatoid arthritis: References: 1. Bristol-Myers Squibb. ORFUCIA® (abatacept) SmP2 2012. 2. Weinblart ME, Schiff M, Valente R, *et al. Arthritis Rheum*; 2013;65(1):28-38. 3. Thaler KJ, Gartlehner G, Ken C, *et al.* Drug Class Review: Targeted Immune Modulators: Final Lipdate 3 Report Internet], Portland (OR): Oregon Health & Science University. 2012; Mar. 4. Chor FH. *Clin Exp Rheumatol* 2008;27(3):510-518. 5. Moreland LW, Atten R, Van den Bosch F, *et al. Arthritis Rheum*: 2002;46(6):1470-1478. 6. Emery P. *Expert Opin Investig Drugs*: 2003;12(4):673-681. 7. Weisman MH, Durez P, Hallegua D, *et al. J. Rheumatol*: 2006;33(11):2162-2166.

427UK13PR02180-01 March 2013 UK0C-135867-03


ORENCIA® (abatacept) **PRESCRIBING INFORMATION**


See Summary of Product Characteristics before prescribing.

PRESENTATION: 250 mo powder for concentrate for solution for IV infusion containing 250 mo abatacent per vial. Each ml contains 25 mo of abatacent after reconstitution; 125 mo ore-filled svringe for SC injection. Each ore-filled svringe contains 125 mg of abatacent in 1 ml. INDICATION: Rheumatoid arthritis (IV infusion and SC pre-filled svringe): Treatment of moderate to severe active rheumatoid arthritis (RA). in combination with methotrexate, in adult patients who have responded inadequately to previous therapy with one or more disease-modifying anti-rheumatic druos (DMARDs) including methotrexate (MTX) or a Tumour Necrosis Factor (TNF) -alpha inhibitor. A reduction in the progression of joint damage and improvement of physical function have been demonstrated during combination treatment with abatacept and methotrexate. See SmPC. Polyarticular Juvenile Idiopathic Arthritis (pJIA) {IV infusion only}: Orencia 250 mg powder for concentrate for solution for infusion is indicated for treatment of moderate to severe active pJIA in paediatric patients 6 years of age and older who have had an insufficient resonnse to other DMARDs including at least one TNF inhibitor. DOSAGE and ADMINISTRATION: Treatment should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of RA. Orencia 250 mg powder for concentrate for solution for IV infusion Adults and elderly: Patients weighing < 60kg; 500mg (2 vials). Patients weighing \geq 60kg \leq 100kg; 750mg (3 vials). Patients weighing > 100kg; 1000mg (4 vials). *Treatment of pJIA*: Paediatric patients, 6 to 17 years of age, weighing less than 75 kg; 10 mg/kg paediatric patients weighing 75 kg or more: to be administered adult dosage, not exceeding a maximum dose of 1,000 mg. See SmPC for details of reconstitution and administration as a 30 minute IV infusion. After initial administration. Orencia should be given at 2 and 4 weeks, then every 4 weeks thereafter. *Children*: Use in children below 6 years of age is not recommended. Orencia 125 mo solution for injection (SC pre-filled svringe) Adults and elderly: Treatment should be initiated with a loading dose using an intravenous infusion. Following this loading dose. the first 125 mo subcutaneous injection of Orencia should be given within a day, then 125 mo subcutaneous injections once weekly. Patients who are unable to receive an infusion may initiate weekly injections of subcutaneous Orencia without an intravenous loading dose. Patients transitioning from Orencia IV therapy to SC administration should administer the first subcutaneous dose instead of the next scheduled intravenous dose. Children: Administration in children below 18 years of ace is not recommended. The continuation of treatment with abataceot should be re-assessed if patients do not respond within 6 months. CONTRAINDICATIONS: Hypersensitivity to the active substance or excipients. Severe and uncontrolled infections such as sepsis and opportunistic infections. WARNINGS AND PRECAUTIONS: Allergic Reactions: Caution in patients with a history of allergic reactions. Orencia should be discontinued if a patient develops serious allergic or anaphylactic reaction. Infections: Caution should be exercised when considering the use in patients with a history of frequent infections, or underlying conditions which may promot to infection. Treatment with Orencia should not be initiated with patients with active infections until infections are controlled. Screening for tuberculosis and hepatitis B should be performed prior to therapy. Any patient who develops a new infection should be closely monitored and Orencia should be discontinued if a patient develops a serious infection. Monitor patients for sions of infection when transitioning from TNF-antagonist to Orencia. Co-administration of Orencia with biologic immunosuppressive or immunomodulatory agents could potentiate the effects of abatacept on the immune system. Treatment with immunosuppressive therapy may be associated with progressive multifocal leukoencephalopathy (PML). Orencia treatment should be discontinued if neurological symptoms suggestive of PML occur, and appropriate diagnostic measures initiated. Malignancies: The potential role of Orencia in the development of malignancies is unknown, see SmPC. Elderly: Caution should be used when treating elderly patients due to a higher incidence of infections and malignancies in this patient group. Autoimmune processes: Theoretical risk of deterioration in autoimmune disease. Immunisation: Live vaccines should not be given simultaneously or within 3 months of discontinuation of Orencia. See SmPC. DRUG INTERACTIONS: Concomitant therapy of Orencia with a TNF-inhibitor is not recommended. No major safety issues were identified with the use of Orencia in combination with sulfasalazine, hydroxychloroquine or leflunomide. PREGNANCY AND LACTATION: Do not use in pregnancy unless clearly necessary. Women should use contraception and not breastfeed during treatment and for up to 14 weeks after last dose treatment. UNDESIRABLE EFFECTS: In adult placebo-controlled trials the following adverse drug reactions were reported Very Common (> 1/10): upper respiratory tract infection including tracheitis, nasopharynoitis, Common (> 1/10): Lower respiratory tract infection (including bronchitis), urinary tract infection, herpes simplex, rhinitis, pneumonia, influenza, leukopenia, headache, dizziness, paraesthesia, conjunctivitis, hypertension, flushing, blood pressure increased, cough, abdominal pain. diarrhoea. nausea. dvspeosia. mouth ulceration, aphthous stomatitis, vomiting, liver function test abnormal (including transaminases increased), rash (including dermatitis), alopecia, pruritus, pain in extremity, fatigue, asthenia, injection site reactions. Uncommon (≥ 1/1,000 to < 1/100): Tooth infection, onychomycosis, herpes zoster, sepsis, musculoskeletal infections, skin abscess, oveloneohritis, pelvic inflammatory disease, basal cell carcinoma, skin papilloma, thrombocytopenia, hypersensitivity, depression, anxiety, sleep disorder, migraine, dry eve, visual acuity reduced, vertigo, palpitations, tachycardia, bradycardia, hypotension, hot flush, vasculitis, blood pressure decreased, bronchospasm, wheezing, dyspnea, gastritis, increased tendency to bruise, dry skin, urticaria, psoriasis, arthralgia, amenorrhagia, influenza like illness, weight increased. Rare (> 1/10,000 to < 1/1,000): Bacteraemia, gastrointestinal infection, lymphoma, lung neoplasm malignant, throat tightness. See SmPC for further details. LEGAL CATEGORY: POM MARKETING AUTHORISATION NUMBER AND BASIC NHS PRICE: Orencia 250 mg concentrate for solution for infusion - EU/1/07/389/001, 1 vial pack: £302.40 Orencia 125 mg solution for Injection - EU/1/07/389/008, 4 pre-filled syringes with needle guard: £1209.60. MARKETING AUTHORISATION HOLDER: Bristol-Myers Squibb Pharma EEIG, Uxbridge Business Park, Sanderson Road, Uxbridge, Middlesex UB8 1DH. Tel: 0800-731-1736. DATE OF PREPARATION: October 2012. Job No: 427UK12PM087

> Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Bristol-Myers Squibb Pharmaceuticals Ltd Medical Information on 0800 731 1736 or medical.information@bms.com.

The ICC and Symphony hall plan





General information

Registration opening hours

Monday 22 April	16.00 - 20.00
Tuesday 23 April	07.30 - 19.30
Wednesday 24 April	07.00 - 18.30
Thursday 25 April	07.00 - 18.30

Exhibition opening hours

Tuesday 23 April	08.30 - 17.30
Wednesday 24 April	08.30 - 17.45
Thursday 25 April	08.45 - 15.00

Badges

Your name badge gives you access to any sessions on the days for which you have registered at **Rheumatology 2013.** You can access the exhibition hall during open hours. It is essential that you visibly display your badge at all times as stewards will not allow people without badges to access sessions or exhibition areas.



CPD

The conference is accredited by the Royal College of Physicians and will accrue you the following:

Tuesday 23 April	6
Wednesday 24 April	6
Thursday 25 April	6

A certificate of attendance is included in your delegate bag. Please make sure that your badge is scanned at least once each day that you are at the conference, so you receive your CPD points. Scanners will be available at the registration desks and at the entrance of the exhibition area in Hall 3.

CPD for Essentials in Rheumatology

In order to receive CPD recognition for attending the Essentials programme, please ensure that you are scanned in to the room before each session.

Abstract supplement

All accepted abstracts have been published as a supplement in the journal *Rheumatology*. Subscribers to the journal will also be able to access abstracts online at:

http://rheumatology.oxfordjournals.org

Catering

Your registration fee for the conference includes lunch and tea and coffee for each day that you are registered. All catering will be served within the main exhibition in Hall 3 (see Exhibition floorplan on page 137 for location). Please refer to the "Conference at a glance" section for timings.

Accommodation

If you have booked through our appointed accommodation agents, HG3, you can contact them directly with queries on: Telephone: 01423 855 990 Email: info@hg3.co.uk

Speaker preview

All speakers are asked to check in their presentation at the speaker preview room no later than two hours prior to your session start time. The speaker preview room is located in the Media Suite of The ICC (see the venue map on page 8 for location). If your session is first thing in the morning, you may want to check in your presentation the night before. Speaker badges can be picked up from the registration desk outside Hall 3.

Cyber café

The cyber café, kindly sponsored by A. Menarini Pharma UK S.R.L, will be situated in the exhibition area in Hall 3 and is free for all delegates to use. Check your emails and comment on BSR's social media channels.

Social Media

We encourage your use of social media in and around **Rheumatology 2013.** Search on Twitter for the hashtag **#Rheum2013** to follow the feed of tweets related to the conference and be sure to include **#Rheum2013** in any tweets that you send out. Happy tweeting!

Room capacities

We have tried to allocate rooms to ensure that the room size is appropriate for the session, based on the information given to us by delegates when they book. We apologise in advance if you are not able to attend a session because the room is full.

Press area

The Rheumatology 2013 press area is situated within the Media Suite (see venue map on page 8). Journalists can use the area to issue press releases and as a meeting point. On request, the Events team can organise one-to-one interviews with key speakers and spokespeople at the conference, subject to availability.

Business centre

The ICC business centre is open for use from 08.45 to 16.45 Tuesday to Thursday. Fax, photocopying, internet access and other business services are available here. See the venue map on page 8) for its location.

The ICC Wi-Fi service

Wi-Fi is available throughout The ICC.

Local information

If your query relates to The ICC or the local area, please visit The ICC information desk, located at the business centre. See the venue map on page (insert page number) for its location.

Property and cloakroom

Delegates are responsible for their property at all times. Neither the BSR nor the venue can accept liability for loss or damage of personal items. Please keep bags and packages with you at all times or use the cloakroom provided. The main cloakroom will be open and available for all conference delegates. The cost of this service is £1 per item. Unattended items can cause unnecessary security alerts.

Prayer space

A prayer room is located off the mall, to the left of the Oak Kitchen servery. This room is for use by all religious groups; a sign in the room indicates which direction is east. Please ask at the registration desk for the security keypad code.



Under 16s

Unfortunately it is not permissible for children under the age of 16 to have access to the meeting.

First aid

Trained first-aiders will be on duty throughout the event; please contact one of the event/venue staff in the event of an incident.

Smoking policy

Smoking is not permitted anywhere within The ICC.

Car parking

Parking for the venue is located within The NIA, which is just a short walk away from The ICC. There are four car parks located at The NIA North – King Edward's Road (open 24 hours) South Upper – Sheepcote Street (open 06.45 – 19.00, Monday – Friday) South Lower – St Vincent Street Community Hall – Junction of King Edward's Road and Sheepcote Street (07.00-midnight)

Disclaimer

Please note that BSR and BHPR accept no responsibility for views expressed by speakers at the event.

Conference highlights

ice

23-25 April 2013 | The ICC, Birmingham







LinkedIn Groups BSR Rheumatology 2013

Facebook The British Society for Rheumatology

Please feel free to use social media in and around **Rheumatology 2013**

Share conference highlights Connect with other attendees Suggest sessions to attend and posters to visit Debate key messages Plan to meet up in the Exhibition or at the social events Make suggestions for next year's conference



Keynote speakers



Tuesday 23 April, 14.00 - 16.00 | Keynote: Jewels in the Crown

Mr Bob Ricketts, CBE, Director of NHS Provider Transition (Department of Health), Director of Commissioning support strategy and Market Development (NHS Commissioning Board)

Bob has held a succession of senior posts at the Department of Health, all associated with reform of health services, including patient choice, commissioning (including the NHS Standard Contract), and provision (including leading the Transforming Community Services programme and development of social enterprises in health and social care). He is currently both Director of Provider Transition for the Department of Health and Director of Commissioning Support Services Strategy and Market Development for the NHS Commissioning Board, and will take up the latter post full-time from April 2013. He has featured in the Health Service Journal 100 list of the people with the greatest influence on health policy and the NHS for the last 5 years. He was awarded a CBE in last year's New Year's Honours list.

His interests outside work include local history and archaeology, UK postal history and Cairn Terriers.



Tuesday 23 April, 16.30 - 17.30 | Heberden Round

Prof Caroline Gordon, Professor of Rheumatology at the University of Birmingham and Consultant Rheumatologist at Sandwell and West Birmingham Hospitals NHS Trust and University Hospitals Birmingham NHS Foundation Trust

Caroline Gordon set up the Birmingham lupus cohort soon after her arrival in Birmingham as a clinical lecturer in 1989. She has undertaken clinical work and teaching as a consultant rheumatologist at City Hospital, Sandwell and West Birmingham Hospitals NHS Trust and the Queen Elizabeth Hospital, University Hospital Birmingham Foundation NHS Trust since 1996. She also has a clinic at Birmingham Women's Hospital for women with systemic rheumatic diseases (particularly lupus and anti-phospholipid syndrome but including severe rheumatoid arthritis, systemic sclerosis and vasculitis) in pregnancy and for those who need pre-pregnancy counseling. The Birmingham lupus clinics have been awarded the title of LUPUS UK Centre of Excellence since 2005, the first lupus centre in the UK to receive this award. Caroline Gordon was awarded the title of Professor of Rheumatology at the University of Birmingham in 2007.

Her research programme focuses on systemic lupus ervthematosus but she has contributed to research into inflammatory arthritis, vasculitis, Sjögren's syndrome and anti-phospholipid syndrome as well. Much of her work has focused on disease assessment for clinical trials and outcome studies, particularly the development of the BILAG disease activity index and the epidemiology of lupus. She has been involved in the development of the SLICC/ACR damage index and in the assessment of quality of life in lupus patients using the SF-36 and the Lupus QoL surveys. She has a longstanding interest in improving the treatment of systemic lupus erythematosus and has been involved in organising three investigator led trials. The two UK based trials were IV cyclophosphamide versus oral cyclophosphamide in lupus nephritis (EULAR sponsored) and cyclosporine versus azathioprine in severe SLE (Arthritis Research UK funded). She led the initiative producing EULAR points to consider for conducting clinical trials in SLE and advises the pharmaceutical industry on organising and analysing lupus clinical trials. She has been closely involved in the development of epratuzumab, an anti-CD22 targeted monoclonal antibody therapy for lupus.

She has worked with Lupus UK and Lupus Europe as well as the NIHR to promote patient involvement in clinical trials. She is a consultant to the Centre for Disease Control on epidemiological studies of lupus in the USA, and to Lupus Foundation of America on their clinical trials training programme (POINT). Her other research interests include clinical and laboratory markers of disease flare, the importance of ethnicity in predicting disease susceptibility and long-term outcome, and the health of children born to mothers with lupus. She is a member of the British Isles Lupus Assessment Group (BILAG), the Systemic Lupus International Collaborating Clinics (SLICC), Co-Chair of the European League Against Rheumatism (EULAR) Task Force for Systemic Lupus Erythematosus and has been a member of several British Society for Rheumatology, American College of Rheumatology and Lupus Foundation of America committees for lupus research. She has been the lupus lead on the Arthritis Research UK systemic autoimmune disease clinical study group and Chair of the national Comprehensive Clinical Research Network (CCRN) Immunology and Inflammation Specialty Group for the National Institute for Health Research (NIHR) since 2008.

> "Excellent trainee sessions"

"A priceless opportunity to learn, share experience and reflect. It has changed my concept about various aspects of modern rheumatology, and subsequently my practice has been changed"

"A first-rate conference that is a must for all who treat patients with rheumatological conditions"



Wednesday 24 April, 16.30 – 17.30 | Heberden Oration

Prof Paul Emery, Arthritis Research UK Professor of Rheumatology, Division of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, Director, Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust

Professor Emery is the Arthritis Research UK Professor of Rheumatology and Head of the Academic Division of Rheumatic & Musculoskeletal Disease, University of Leeds and the Director of the Leeds Musculoskeletal Biomedical Research Unit at Leeds Teaching Hospitals Trust, UK.

Professor Emery was President of EULAR 2009-2011, he is currently Past President. He has served on the editorial boards of all the major rheumatology journals. He was inaugural President of ISEMIR (International extremity MRI society). He is an NIHR Senior Investigator. He is a recipient of the Roche Biennial Award for Clinical Rheumatology; the Rheumatology Hospital Doctor of the Year award 1999; and EULAR prize 2002 for outstanding contribution to rheumatology research. In 2012 he was awarded the Carol Nachman Prize.

Professor Emery's research interests centre around the immunopathogenesis and immunotherapy of rheumatoid arthritis, SpA and connective tissue diseases. He has a special interest in the factors leading to persistent inflammation. He has published over 800 peer-reviewed articles in this area.



Thursday 25 April, 11.30 – 13.00 | Droitwich Lecture

Dr Philip Helliwell, Senior Lecturer in Rheumatology at the University of Leeds and Honorary Consultant Rheumatologist for the Bradford Hospitals NHS Trust

Dr Helliwell is co-founder and co-lead for the Bradford (University) Diploma in Rheumatology and Musculoskeletal Medicine and is an active member of the Bradford and Airedale Musculoskeletal Alliance, a tier two service provided to GPs in the designated geographical area.

His previous and current appointments include: Member of NHS R&D Research Committee on Physical and Complex Disabilities, Member of the Executive Council, Centre for Biomechanics and Medical Engineering; Treasurer and Member of Executive Committee, Society for Back Pain Research; Member of Education Committee, Arthritis Research Campaign; and Editor for the ARC Patient Information Leaflets and Convener Publications Working Group, Member of the Heberden Committee, at the British Society for Rheumatology, Member of Council at the British Society for Rheumatology, Member of Executive Committee, Group for Research and Assessment of Psoriasis and Psoriatic arthritis.

His current and past research: treatment paradigms, clinical features and classification of psoriatic arthritis; biomechanics of joints, gait assessment and foot disorders in inflammatory and non-inflammatory arthritis, epidemiology of rheumatic disease with a longitudinal community cohort of low back pain and community based studies of psoriasis and psoriatic arthritis



Thursday 25 April, 14.00 – 15.30 | Commissioning for rheumatology in a cold climate

Prof Paul Corrigan, Former Senior Health Policy Adviser to the Prime Minister Tony Blair and Former Director of Strategy and Commissioning at the London Strategic Health Authority

Paul Corrigan gained his first degree in social policy from the LSE in 1969, his PhD at Durham in 1974. He is currently adjunct professor of public health at the Chinese University of Hong Kong and of health policy and Imperial College London.

For the first 12 years of his working life he taught at Warwick University and the Polytechnic of North London. During this period he taught, researched and wrote about inner city social policy and community development. In 1985 he left academic life and became a senior manager in London local government and in 1997 he started to work as a public services management consultant. In 1998 he published Shakespeare on Management. From July 2001 he worked as a special adviser to Alan Milburn first and then John Reid, the then Secretary of States for Health. At the end of 2005 he became the senior health policy adviser to the Prime Minister Tony Blair Over this six years he was instrumental in developing all the major themes of NHS reform not only in terms of policy levers buy also in developing capacity throughout the NHS to use those levers.

Between June 2007 and March 2009 he was the director of strategy and commissioning at the London Strategic Health Authority.

Since then Paul has been working as a management consultant and an executive coach helping leaders within the NHS create and develop step changes within their organisation. In September 2011 he published a pamphlet "The hospital is dead Long live the Hospital" that was recognised by a leader in the Times as an important contribution to reform. As a columnist for the Health Service Journal he has continued to argue the case for NHS reform. He has an influential blog "Health Matters" that develops these issues.

Rewarding professional excellence, innovations and achievements

Each year BSR and BHPR award a series of prizes to recognize achievements and encourage those working to improve patient care across all levels.



"Winning the prize meant a lot to me personally as it was really nice to gain external recognition for my work." - 2012 Garrod Prize Winner, Mrs Elizabeth Camacho



BSR Prizes and Awards

Michael Mason Prize

The esteemed Michael Mason Prize is awarded by the Heberden Committee for excellence in clinical or scientific research in the field of rheumatology. The winner receives $\pounds 1,000$, the Michael Mason trophy and the opportunity to present their work during the Jewels in the Crown plenary session at Rheumatology 2013.

Osteoarthritis: A multisystem approach to understanding disease pathopysiology

Dr Nidhi Sofat, St George's University of London, London Tuesday 23 April, 14.00 - 16.00, Jewels in the Crown

Garrod Prize

Named after Sir Alfred Baring Garrod, the prestigious Garrod Prize is open to scientists with a non-clinical background currently working in rheumatology or a related discipline. The winner receives £1,000, the Garrod trophy and the opportunity to present their work during the Jewels in the Crown plenary session at Rheumatology 2013.

Domain I, the hidden face of antiphospholipid syndrome Dr Charis Pericleous, University College London, London Tuesday 23 April, 14.00 - 16.00, Jewels in the Crown

"Getting the information about winning the award is one of the happiest moments in my professional career, bringing the sense of being valued for what we do as health professionals."
2012 BSR Allied Health Professional Bursary Winner, Dr Mwidimi Ndosi

BSR Medical Student Bursaries

Awarded to medical students whose abstract submissions were considered to be exceptional by the Heberden Committee. Winners receive complimentary registration to Rheumatology 2013, travel and accommodation and the opportunity to present their work at the conference.

Ms Kelsey Watt, University of Glasgow, Glasgow Can medical students successfully engage with their peers to encourage interest in musculoskeletal medicine and surgery? The first national undergraduate musculoskeletal conference

Ms Qiong Wu, Imperial College London, London T cell depleted autologous stem cell transplantation results in a chimera of clones from before and after transplant in systemic juvenile idiopathic arthritis

Ms Esha Abrol, University College London, London A retrospective study of long-term outcome in 152 patients with primary Sjögren's syndrome – 25 year experience

Mr Alexander Warner, University of Manchester, Manchester Are patients with inflammatory polyarthritis experiencing the same reductions in cardiovascular specific mortality as the general population?

Young Investigator Awards

Intended to encourage the work of investigative rheumatologists at an early stage of their careers, these prizes reward those who have submitted an imaginative hypothesis with results that could advance knowledge within the field. Winners receive complimentary registration to Rheumatology 2013 and the opportunity to present their work at the conference. **Mr Martin Fitzpatrick**, University of Birmingham, Birmingham Macrophage metabotypes in the hypoxic inflammatory environment assessed using metabolomic profiling Thursday 25 April, 12.00-12.15, Oral abstracts: Science

Dr Elena Lugli, Kennedy Institute of Rheumatology, University of Oxford, Oxford *Widespread citrullination in healthy and inflamed lung tissue as a priming site for autoimmunity in RA* Tuesday 23 April, 12.15-12.30, Oral abstracts: Pathogenesis

Mr Jonathan Baker, Newcastle University, Newcastle The role of protein kinase D signalling in the induction of matrix metalloproteinases in human articular chondrocytes Thursday 25 April, 11.30-11.45, Oral abstracts: Science

abbvie

BSR Innovation Award, supported by AbbVie

Introduced in 2005, this award acknowledges innovation and excellence that have benefited rheumatology medicine. The winner receives ± 500 , complimentary registration to Rheumatology 2013 and the opportunity to present their work at the conference.

Dr Muhammad Haroon, St Vincent's University Hospital, Dublin

A proposed algorithm and its performance evaluation for the best referral by ophthalmologists of acute anterior uveitis patients with possible underlying spondyloarthropathy Thursday 25 April, 15.00 - 15.15, Oral abstracts: Spondyloarthritis





BHPR Clinical Prize, supported by Algeos

Designed to recognise outstanding clinical work, best practice, and improved patient care, the BHPR Clinical Prize winner receives $\pounds700$ and complimentary registration to Rheumatology 2013.

Mrs Katie McAlarey, Victoria Hospital, Glasgow Scottish Society of Rheumatology (SSR) occupational therapy rheumatoid arthritis (RA) work audit

BHPR Student / Recently Qualified Health Professional Prize

This prestigious annual award is for a piece of work that is of outstanding quality for a person at this stage in their career. The winner receives £150 complimentary registration for Rheumatology 2013 and travel expenses.

Mr Nicholas Walker, King's College London, London Patients' perceptions of a brief physiotherapist-delivered treatment incorporating psychological flexibility for chronic low back pain: a qualitative study

Arthritis Research UK Silver Medal Research Prize

Awarded for a piece of research which is of the highest quality and makes an overall contribution to rheumatology.

Dr Ruth Barn, Glasgow Caledonian University, Glasgow Tibialis posterior tenosynovitis and associated pes plano valgus in rheumatoid arthritis: EMG, multi-segment foot kinematics and ultrasound features

Arthritis Research UK Silver Medal Physiotherapy Prize

Presented for a piece of research or clinical work that is of the highest quality and makes a significant contribution to rheumatology physiotherapy.

Miss Catharine Sian MacRae, Chelsea and Westminster Hospital, London

Rocker sole shoes are no more beneficial than flat sole shoes in the management of chronic low back pain

The BHPR prize ceremony will take place during the Droitwich session, Thursday 25 April, 11.30 – 13.00. Other prizes presented during this session will be:

Arthritis Research UK Nursing Prize

presented to Dr Seamus O'Brien, Belfast Health and Social Care Trust, Belfast

Arthritis Research UK Podiatry Prize

presented to Ms Kym Hennessy, Glasgow Caledonian University, Glasgow

Arthritis Research UK Occupational Therapy Prize

presented to Mrs Lucia Ramsey, University of Ulster, Jordanstown

NRAS Patients in Focus Awards 2013

presented to Mrs Sue Kennedy and Mrs Anne Hardy, Royal Derby Hospital, Derby



The BSR and BHPR would like to thank all of the judges who have given up their time to assess the prizes at **Rheumatology 2013**

BSR Prizes and bursaries

Mr Michael Backhouse Dr Lindsay Bearne Dr Hector Chinoy Prof Ian Clark Dr Jacqui Clinch Dr Chris Deighton **Prof Chris Denton** Dr Emmanuel George Prof Elaine Hay Dr Sabrina Kapoor Prof Gary Macfarlane Prof Robert Moots Dr Ben Parker Dr Colin Pease Prof Costantino Pitzalis Dr Elizabeth Price Dr Ed Roddy Dr Nicholas Shenker Dr David Walker Dr Karen Walker-Bone Prof Gerry Wilson

BHPR Prizes and bursaries

Dr Jo Adams Dr Mike Backhouse Mrs Cathy Ball Dr Lindsay Bearne Dr Fiona Cramp Dr Krysia Dziedzic Mr Robert Field Ms Jill Firth Dr Caroline Flurey Mrs Sue Gurden Mrs Lindsay Hawley Dr Melanie Holden Miss Lindsey Hooper

Poster Category and Tours

Tuesday 23 April 2013	
Tuesday 23 April 2013 Case reports Imaging Metabolic and crystal arthropathies Rheumatoid arthritis: clinical features Rheumatoid arthritis: comorbidities Rheumatoid arthritis: pathogenesis and animal models	1 - 24 25 - 29 30 - 34 35 - 45 46 - 60 61 - 68
Rheumatoid arthritis: treatment	69 - 102

Wednesday 24 April 2013

BHPR - Audit and clinical evaluation	103 - 113	
BHPR Research: qualitative	114 – 125	
BHPR Research: quantitative	126 - 143	
Biology of bone, cartilage and connective tissue disease	144	
Education	145 – 157	
Osteoporosis and metabolic bone disease	158 - 165	
Paediatric and adolescent rheumatology	166 - 175	
Pain	176 - 181	
Primary Care	182 - 183	
SLE and antiphospholipid syndrome	184 – 207	

Thursday 25 April 2013

Basic Science Cell receptor-ligand interaction, signalling, activation	208 - 213 214 - 217
and apoptosis Cytokines and inflammatory mediators	218 – 220
Epidemiology	221 – 228
Genetics	229 – 233
Health services research, economics and outcomes research	234 - 246
Miscellaneous rheumatic diseases	247 – 252
Muscle Disorders	253 – 254
Osteoarthritis: clinical features	255 – 258
Osteoarthritis: pathogenesis and animal models	259 - 260
Osteoarthritis: treatment	261 - 263
Scleroderma and related disorders	264 - 273
Sjögren's syndrome and other connective tissue disorders	274 - 275
Soft tissue and regional musculoskeletal disease, fibromyalgia	276 – 277
Spondylarthropathies (including psoriatic arthritis)	278 - 303
Vasculitis	304 - 308

A poster drop off/pick up and hanging service is available at the poster registration desk. Drop off your poster the day prior to your session and one of our poster staff will hang it for you.



oo

Poster tours 2013

Our poster tours are guided by leaders in the field and will be highlighting a selection of BSR and BHPR posters helping delegates make the most of poster viewing sessions. Each tour will take around 45 minutes and will consist of approximately 8 carefully selected high scoring abstracts.

Places on the tours are limited, so please register in advance at the registration desk.

umato

Tuesday 23 April 2013 10.40 – 11.25

Tour RA clinical RA pathogenesis Case reports

Wednesday 24 April 2013 10.40 – 11.25

Tour BHPR SLE and antiphospholipid syndrome Education

Thursday 25 April 2013 10.40 – 11.25 Tour Epidemiology Connective tissue disease Spondyloarthropathy Leader Dr Maya Buch Dr Andrew Filer Dr Robert Thompson

Leader Dr Catherine Bowen Prof David D'Cruz Prof Andrew Hassell

Leader Dr Karen Walker-Bone Prof Ariane Herrick Prof Paul Bowness

NEW Innovation Theatre sessions

New for 2013 the BSR are excited to introduce the Innovation Theatre, which will be based within the exhibition hall where concise 30 minute sessions will take place and be hosted by our exhibitors. Sessions are free to attend to all registered delegates, subject to capacity. Details of sessions are listed below:

Tuesday 23 April 2013

11.00 | Roche ANCA-associated vasculitis for Rheumatologists Speaker: Prof David G I Scott

- 13.00 | AbbVie Talking AS, online ankylosing spondylitis assessment for your patients Speaker: Dr Raj Sengupta
- 13.30 | Savient Pharma Ireland Management of Chronic Tophaceous Gout Speaker: Dr Robert T Keenan

Wednesday 24 April 2013

10.30 | Roche Combination therapy in RA: Methotrexate debate Speaker: Prof Ernest Choy

11.00 | Medac Early aggressive use of subcutaneous methotrexate: Financial and health benefits Speaker: Dr Sandeep Bawa

Thursday 25 2013 April

10.30 | Celgene

Looking inside the cell for a new perspective on Psoriatic Arthritis Speakers: Prof Miles D Houslay and Prof Oliver Fitzgerald

13.00 | AbbVie

Talking AS, online ankylosing spondylitis assessment for your patients Speaker: Dr Raj Sengupta







Conference Dinner Shimla Pinks Restaurant, Broad Street Wednesday 24 April, 19.30

BSR and BHPR invite you to enjoy an exciting evening of socialising over a gourmet three-course Indian feast. Your entertainment will include Indian music and a chance to try Bollywood dancing. Limited tickets are available from the registration desk £40 (inc VAT)



Oral presentation of abstacts

icc





Rheumatology 2014 is the UK's leading rheumatology event. It offers you an unparalleled opportunity to expand your knowledge and network with other specialist health professionals.





29 April-1 May | Liverpool, UK

Be a part of **Rheumatology 2013:** contribute by submitting an abstract or conference session proposal. Or just tell us what sessions you'd like us to include.

www.rheumatology.org.uk/conference

Conference session proposal deadline: Friday 17 May 2013 Abstract deadline: Friday 15 November 2013 Early bird registration until Friday 31 January 2014





Abstract Reviewers

The BSR Heberden Committee was expanded substantially for the purposes of abstract assessment to ensure that every abstract was peer reviewed, blind, by at least three reviewers. The Heberden Committee is extremely grateful for the assistance of everyone who gave up their time to review abstracts and acknowledges them accordingly:

Heberden Committee

Prof Chris Denton Prof Costantino Pitzalis Prof Robert Moots Dr Jacqui Clinch Mr Michael Backhouse Dr Lindsay Bearne Dr Emmanuel George Dr Ben Parker Prof Ian Clark Prof Elaine Hay

Prof David Abraham Dr Nicole Amft Dr Marina Anderson **Dr Jacqueline Andrews** Prof Nigel Arden Ms Cathy Ball Prof Anne Barton Dr Rupa Bessant Dr Fraser Birrell Prof Ray Boot-Handford Dr Cathy Bowen Dr Simon Bowman Dr Paul Bowness Prof Matt Brown Prof Ian Bruce Prof Christopher Buckley Dr Maresa Carulli Prof Tim Cawston Prof Kuntal Chakravarty **Prof Ernest Choy** Prof Philip Conaghan **Prof Andy Cope** Dr Fiona Cramp **Prof Peter Croft** Dr Lorraine Croot Prof Bhaskar Dasgupta Dr Joel David

Dr Ed Roddy Prof Gary Macfarlane Dr Hector Chinoy Dr Nicholas Shenker Dr Karen Walker-Bone Dr Colin Pease Dr David Walker Dr Elizabeth Price Prof Gerry Wilson Dr Sabrina Kapoor

Dr Julie Dawson **Prof Chris Deighton** Mrs Jill Firth Dr Karl Gaffney **Dr Bridget Griffiths** Dr Frances Hall Dr Alison Hammond Dr Inam Hag Prof Elaine Hay Dr Ariane Herrick Dr Melanie Holden Dr Alan Holmes Miss Lindsey Hooper Dr Philippa Hulley Dr Kimme Hyrich Dr John Ioannou Dr Paresh Jobanputra Dr Jeremy Jones Dr Andrew Keat Dr Patrick Kielv Dr George Kitas Dr Ellie Korendowych Dr Helen Lachmann Dr Peter Lanvon Dr Thomas Lawson Dr John McBeth Dr Dennis McGonagle Prof Ian McInnes Prof Ann Morgan Dr Chetan Mukhtyar Dr Fai Ng Dr Brian Noble Dr Voon Ong Dr Jon Packham Dr Blandine Poulet Dr Ben Rhodes Dr Ruth Richmond Dr Ed Roddy Ms Tessa Sanderson Dr Giovanni Sanna Dr Benjamin Schreiber Prof David L. Scott Dr Millicent Stone Prof Deborah Symmons Prof Jonathan Tobias Prof Jacob Van Laar Prof Tonia Vincent **Dr Richard Watts** Dr Anita Williams Dr Lyn Williamson Dr Elspeth Wise **Prof Jane Worthington** Dr Adam Young



29 April-1 May | Liverpool, UK

Registration is now open for **Rheumatology 2014**

Take advantage of the special advance ticket price for next year's conference, where you'll enjoy an extensive programme of sessions on cutting-edge subjects and the opportunity to network with colleagues from across the country.



Special advance rate available only until Sunday 30 June 2013

Book now at **www.rheumatology.org.uk/conference** (use the conference cyber café or register at BSR's stand 44)





State of the art 2013

A unique conference focused on interactive cases led by world experts

Edinburgh International Conference Centre

3-4 October 2013



The British Society for Rheumatology announces the launch of Clinical Rheumatology State of the Art 2013

This international summit will bring together consultants and next generation rheumatologists to share and exchange clinical best practice through high-level round-table discussion groups, debate and expert panel sessions.

www.crsa2013.org



The BSR Biologics Registers



The BSR Biologics Registers

Please support these BSR projects by recruiting the following patients:

Drug	Diagnosis	Biologic Naive?	Contact
ETANERCEPT	RA/AS	MUST be biologic naive	RA - Manchester AS - Aberdeen
Adalimumab	RA/AS	MUST be biologic naive	RA - Manchester AS - Aberdeen
CERTOLIZUMAB	RA	Can be first or second line therapy	Manchester
TOCILIZUMAB	RA	Can be first or second line therapy	Manchester
INFLIXIMAB	RA	MUST be biologic naive	Manchester

To recruit patients, or for more information, please contact:

- Rheumatoid Arthritis: biologics.register@manchester.ac.uk
- Ankylosing Spondylitis: bsrbr-as@abdn.ac.uk





¥ 2

Google



STATE OF THE ART 2013

A unique conference focused on interactive cases led by world experts

Edinburgh International Conference Centre

3-4 October 2013



The British Society for Rheumatology announces the launch of Clinical Rheumatology State of the Art 2013

This international summit will bring together consultants and next generation rheumatologists to share and exchange clinical best practice through high-level round-table discussion groups, debate and expert panel sessions.

www.crsa2013.org



BSR Membership

Join us at **Stand** 44





Ways to join:

Online www.rheumatology.org.uk Email subscriptions@rheumatology.org.uk Request an **application pack** by phone **020 7842 0900**



What existing members say about us

"It is the most supportive and active medical organisation that I belong to" – BSR Member 2012



Benefits:

- 12 issues of *Rheumatology* with online access
- Expert commissioning support and leadership
- Regional Representation
- Special interest groups
- Regular e-communications
- **Discounted rates** for the annual conference, including a special rate for trainees
- Discounted rates for
 education courses
- Access to publications
 and guidelines
- E-Learning

